NR 565 WEEK 4 MIDTERM EXAM LATEST
UPDATES QUESTIONS WITH CORRECT
ANSWERS|AGRADE
Chapter 7. Cultural and Ethnic Influences in Pharmacotherapeutics
1. Cultural factors that must be taken into account when prescribing include(s): Who the decision
maker is in the family regarding health-care decisions
Attitudes regarding the use of drugs to treat illness
The patient’s view of health and illness
2. Ethnic differences have been found in drug: Hepatic metabolism
3. The National Standards of Culturally and Linguistically Appropriate Services are required to
be implemented in all:
Organizations that receive federal funds
4. According to the National Standards of Culturally and Linguistically Appropriate Services, an
interpreter for health care:
Must be a professionally trained medical interpreter
5. According to the U.S. Office of Minority Health, poor health outcomes among African
Americans are attributed to:
Discrimination, cultural barriers, and lack of access to health care
6. The racial difference in drug pharmacokinetics seen in American Indian or Alaskan Natives
are:
Largely unknown due to lack of studies of this population
7. Pharmacokinetics among Asians are universal to all the Asian ethnic groups. False
8. Alterations in drug metabolism among Asians may lead to:
Slower metabolism of antidepressants, requiring lower doses
9.Asians from Eastern Asia are known to be fast acetylators. Fast acetylators:
Require higher doses of drugs metabolized by acetylization to achieve efficacy
10. Hispanic native healers (curanderas):
Use herbs and teas in their treatment of illness
Chapter 8. An Introduction to Pharmacogenomics
1. Genetic polymorphisms account for differences in metabolism, including:
, Poor metabolizers, who lack a working enzyme
Intermediate metabolizers, who have one working, wild-type allele and one
mutant allele
Extensive metabolizers, with two normally functioning alleles
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
Increased dosages needed of drugs metabolized by 2D6, such as the selective
serotonin reuptake inhibitors
3. Rifampin is a nonspecific CYP450 inducer that may:
Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
failure
4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Increased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to: Decreased
response to warfarin
6. Genetic testing for VCORC1 mutation to assess potential warfarin resistance is required prior
to prescribing warfarin. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to
prescribing: Cetuximab
8. Carbamazepine has a Black Box Warning recommending testing for the HLA-B*1502 allele in
patients with Asian ancestry prior to starting therapy due to:
Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502
allele
9. A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated
by the body may lead to:
Increased adverse drug reactions, such as neutropenia 10.
Patients who have a poor metabolism phenotype will have:
Slowed metabolism of a prodrug into an active drug, leading to accumulation of
prodrug
11. Ultra-rapid metabolizers of drugs may have:
Active drug rapidly metabolized into inactive metabolites, leading to potential
therapeutic failure
12. A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast
cancer to:
Reduce the likelihood of therapeutic failure with tamoxifen treatment
, Chapter 1. The Role of the Nurse Practitioner
1. Nurse practitioner prescriptive authority is regulated by: The State Board of Nursing for each
state
2. The benefits to the patient of having an Advanced Practice Registered Nurse (APRN)
prescriber include:
Nurses care for the patient from a holistic approach and include the patient in
decision making regarding their care
3. Clinical judgment in prescribing includes:
Factoring in the cost to the patient of the medication prescribed
4. Criteria for choosing an effective drug for a disorder include:
Consulting nationally recognized guidelines for disease management
5. Nurse practitioner practice may thrive under health-care reform because of:
The demonstrated ability of nurse practitioners to control costs and
Improve patient outcomes
Chapter 4. Legal and Professional Issues in Prescribing
1. The U.S. Food and Drug Administration regulates:
The official labeling for all prescription and over-the-counter drugs
2. The U.S. Food and Drug Administration approval is required for: Medical devices, including
artificial joints
3. An Investigational New Drug is filed with the U.S. Food and Drug Administration: Prior to
human testing of any new drug entity
4. Phase IV clinical trials in the United States are also known as: Postmarketing research
5. Off-label prescribing is:
Legal if there is scientific evidence for the use
6. The U.S. Drug Enforcement Administration:
Registers manufacturers and prescribers of controlled substances
7. Drugs that are designated Schedule II by the U.S. Drug Enforcement Administration: May
not be refilled; a new prescription must be written
8. Precautions that should be taken when prescribing controlled substances include: Using
tamper-proof paper for all prescriptions written for controlled drugs
UPDATES QUESTIONS WITH CORRECT
ANSWERS|AGRADE
Chapter 7. Cultural and Ethnic Influences in Pharmacotherapeutics
1. Cultural factors that must be taken into account when prescribing include(s): Who the decision
maker is in the family regarding health-care decisions
Attitudes regarding the use of drugs to treat illness
The patient’s view of health and illness
2. Ethnic differences have been found in drug: Hepatic metabolism
3. The National Standards of Culturally and Linguistically Appropriate Services are required to
be implemented in all:
Organizations that receive federal funds
4. According to the National Standards of Culturally and Linguistically Appropriate Services, an
interpreter for health care:
Must be a professionally trained medical interpreter
5. According to the U.S. Office of Minority Health, poor health outcomes among African
Americans are attributed to:
Discrimination, cultural barriers, and lack of access to health care
6. The racial difference in drug pharmacokinetics seen in American Indian or Alaskan Natives
are:
Largely unknown due to lack of studies of this population
7. Pharmacokinetics among Asians are universal to all the Asian ethnic groups. False
8. Alterations in drug metabolism among Asians may lead to:
Slower metabolism of antidepressants, requiring lower doses
9.Asians from Eastern Asia are known to be fast acetylators. Fast acetylators:
Require higher doses of drugs metabolized by acetylization to achieve efficacy
10. Hispanic native healers (curanderas):
Use herbs and teas in their treatment of illness
Chapter 8. An Introduction to Pharmacogenomics
1. Genetic polymorphisms account for differences in metabolism, including:
, Poor metabolizers, who lack a working enzyme
Intermediate metabolizers, who have one working, wild-type allele and one
mutant allele
Extensive metabolizers, with two normally functioning alleles
2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
Increased dosages needed of drugs metabolized by 2D6, such as the selective
serotonin reuptake inhibitors
3. Rifampin is a nonspecific CYP450 inducer that may:
Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic
failure
4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Increased levels of a coadministered drug, such as digoxin, that requires P-
glycoprotein for absorption and elimination
5. Warfarin resistance may be seen in patients with VCORC1 mutation, leading to: Decreased
response to warfarin
6. Genetic testing for VCORC1 mutation to assess potential warfarin resistance is required prior
to prescribing warfarin. False
7. Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to
prescribing: Cetuximab
8. Carbamazepine has a Black Box Warning recommending testing for the HLA-B*1502 allele in
patients with Asian ancestry prior to starting therapy due to:
Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502
allele
9. A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated
by the body may lead to:
Increased adverse drug reactions, such as neutropenia 10.
Patients who have a poor metabolism phenotype will have:
Slowed metabolism of a prodrug into an active drug, leading to accumulation of
prodrug
11. Ultra-rapid metabolizers of drugs may have:
Active drug rapidly metabolized into inactive metabolites, leading to potential
therapeutic failure
12. A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast
cancer to:
Reduce the likelihood of therapeutic failure with tamoxifen treatment
, Chapter 1. The Role of the Nurse Practitioner
1. Nurse practitioner prescriptive authority is regulated by: The State Board of Nursing for each
state
2. The benefits to the patient of having an Advanced Practice Registered Nurse (APRN)
prescriber include:
Nurses care for the patient from a holistic approach and include the patient in
decision making regarding their care
3. Clinical judgment in prescribing includes:
Factoring in the cost to the patient of the medication prescribed
4. Criteria for choosing an effective drug for a disorder include:
Consulting nationally recognized guidelines for disease management
5. Nurse practitioner practice may thrive under health-care reform because of:
The demonstrated ability of nurse practitioners to control costs and
Improve patient outcomes
Chapter 4. Legal and Professional Issues in Prescribing
1. The U.S. Food and Drug Administration regulates:
The official labeling for all prescription and over-the-counter drugs
2. The U.S. Food and Drug Administration approval is required for: Medical devices, including
artificial joints
3. An Investigational New Drug is filed with the U.S. Food and Drug Administration: Prior to
human testing of any new drug entity
4. Phase IV clinical trials in the United States are also known as: Postmarketing research
5. Off-label prescribing is:
Legal if there is scientific evidence for the use
6. The U.S. Drug Enforcement Administration:
Registers manufacturers and prescribers of controlled substances
7. Drugs that are designated Schedule II by the U.S. Drug Enforcement Administration: May
not be refilled; a new prescription must be written
8. Precautions that should be taken when prescribing controlled substances include: Using
tamper-proof paper for all prescriptions written for controlled drugs
